Natamycin niosomes as a promising ocular nanosized delivery system with ketorolac tromethamine for dual effects for treatment of candida rabbit keratitis;<i>in vitro</i>/<i>in vivo</i>and histopathological studies

El-Nabarawi, Mohamed A.; Rehem, Randa Tag Abd El; Teaima, Mahmoud H.; Abary, Mohammed Y.S.; El-Mofty, Hala Mohammed; Khafagy, Mohamed M; Lotfy, Nancy M; Salah, Mona

doi:10.1080/03639045.2019.1579827

Cited by 52 publications

(29 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prepared dispersion was positioned into a centrifuge device and was centrifuged at 12,000 rpm for 30 min. The supernatant was analyzed by UV spectrophotometer (UV 1800, Shimadzu Japan) to determine the free drug concentration (C free) at 304 nm and dilution was done if required [23]. The %drug entrapped (EE) was calculated using the following equation:…”

Section: Drug Entrapment Efficiencymentioning

confidence: 99%

Ocular delivery of natamycin based on monoolein/span 80/poloxamer 407 nanocarriers for the effectual treatment of fungal keratitis

Kazi¹,

Dhakne²,

Dehghan³

2020

jrp

View full text Add to dashboard Cite

A 3 2 factorial design was used to develop Natamycin cubosome nanoparticles with enhanced corneal permeation, so as to effectively treat ocular fungal keratitis. Probe sonication technique was deployed to disperse the dry lipidic film to obtain colloidal dispersion. The colloidal dispersion was characterized for critical quality attributes such as particle size, poly dispersibility index (PDI), zeta potential and entrapment efficiency. The optimized batch exhibited a particle size of 158.2 nm, zeta potential-40 mV, PDI 0.328 in addition, entrapment efficiency of 99.85%. The in vitro drug release of natamycin from optimized cubosome demonstrated a cumulative %drug release of 84.29% at the end of 8 hours. The optimized cubosomal dispersion exhibited enhanced in vitro antifungal activity against Candida albicans and Aspergillus fumigatus as compared to a pure drug suspension. The optimized formulation was further analyzed for polarized light microscopy (PLM), transmission electron microscopy (TEM) and small angle Xray scattering (SAXS) to state the morphology of formed cubosome nanoparticles and was noted to be Im3m bicontinous cubic mesophasic structure. X-ray diffraction (XRD) studies affirmed the complete encapsulation of natamycin into cubosome vesicles. Ex vivo corneal permeation studies of optimized formulation revealed enhanced corneal permeation in comparison to a pure drug suspension. The ocular irritation studies performed on rabbits indicated the cubosome to be non-irritant. Finally, the developed natamycin cubosome nanoparticles demonstrated sustained drug release and increased corneal penetration. Thus, these cubosome nanocarriers present a propitious delivery system for effective management of ocular fungal keratitis.

show abstract

Section: Drug Entrapment Efficiencymentioning

confidence: 99%

Ocular delivery of natamycin based on monoolein/span 80/poloxamer 407 nanocarriers for the effectual treatment of fungal keratitis

Kazi¹,

Dhakne²,

Dehghan³

2020

jrp

View full text Add to dashboard Cite

show abstract

“…The formulation also showed promising results in the treatment of candida keratitis as compared to other formulations along with combined marketed formulations (Natacyn and Ketoroline). This showed superlative results of the niosomal formulation in all in vitro , in vivo experimental, and histopathological studies [ 26 ].…”

Section: Need For Nanomedicine For Ocular Drug Deliverymentioning

confidence: 97%

Nano-Based Drug Delivery System: Recent Strategies for the Treatment of Ocular Disease and Future Perspective

Qamar

Qizilbash

Iqubal

et al. 2020

DDF

View full text Add to dashboard Cite

The structure of the eye is very complex in nature which makes it a challenging task for pharmaceutical researchers to deliver the drug at the desired sites via different routes of administration. The development of the nano-based system helped in delivering the drug in the desired concentration. Improvement in penetration property, bioavailability, and residence time has all been achieved by encapsulating drugs into liposomes, dendrimers, solid lipid nanoparticle, nanostructured lipid carrier, nanoemulsion, and nanosuspension. This review puts emphasis on the need for nanomedicine for ocular drug delivery and recent developments in the field of nanomedicine along with recent patents published in the past few years.

show abstract

“…The niosomal form showed a controlled release profile, releasing only 20% to 50% of the drug in the first 10 hours compared to the commercial suspension formulation (NATACYN ® 5%) which released more than 90% of the drug in the same amount of time. 49 Table 5 provides a summary of these studies.…”

Section: Fluconazole Pathak Et Al 2013mentioning

confidence: 99%

A Review on Ocular Novel Drug Delivery Systems of Antifungal Drugs: Functional Evaluation and Comparison of Conventional and Novel Dosage Forms

Mehrandish

Mirzaeei

2020

Adv Pharm Bull

View full text Add to dashboard Cite

Ocular fungal infections affect more than one million people annually worldwide. They can lead to impaired vision or even complete blindness, so they should be treated immediately to prevent such consequences. Although topical administration has always been the most common route of ocular drug delivery owing to high patient acceptance, reduced side effects, and the possibility of self-administration, its limited ocular bioavailability poses a major challenge. As a result, attention has recently been drawn to the design and development of novel drug delivery systems (NDDS) that can overcome the challenges of conventional dosage forms. This research is the first to review and classify the studies which have designed and developed topical ocular NDDS with the aim to compare the performance and antifungal activity of these novel systems with conventional forms. According to the results, all studies seemed to confirm the superiority of NDDS over conventional forms in cases of released and permeated drug and antifungal activity. The NDDS were used specifically to improve ocular delivery by slowing down the release rate, increasing drug permeation, and subsequently increasing the antifungal effects of the active pharmaceutical ingredients. Hence, further studies on NDDS may aid the optimization of ocular drug delivery of antifungal drugs.

show abstract

Natamycin niosomes as a promising ocular nanosized delivery system with ketorolac tromethamine for dual effects for treatment of candida rabbit keratitis;in vitro/in vivoand histopathological studies

Cited by 52 publications

References 55 publications

Ocular delivery of natamycin based on monoolein/span 80/poloxamer 407 nanocarriers for the effectual treatment of fungal keratitis

Ocular delivery of natamycin based on monoolein/span 80/poloxamer 407 nanocarriers for the effectual treatment of fungal keratitis

Nano-Based Drug Delivery System: Recent Strategies for the Treatment of Ocular Disease and Future Perspective

A Review on Ocular Novel Drug Delivery Systems of Antifungal Drugs: Functional Evaluation and Comparison of Conventional and Novel Dosage Forms

Contact Info

Product

Resources

About